What's Happening?
Advanced Biomed Inc. has introduced the A+PerfusC™ system, a perfusion-based 3D cell culture platform designed to replicate human physiological conditions for precision medicine and drug discovery. The system supports continuous culture, promoting spheroid and organoid formation for enhanced cell viability and drug response predictability. It offers applications in personalized oncology research, drug screening, and regenerative medicine. The platform aims to improve disease modeling and accelerate treatment development.
Why It's Important?
The A+PerfusC™ system represents a significant advancement in biomedical research, offering more accurate models of human tissue for drug testing and disease study. By enhancing cell culture conditions, the platform can improve the reliability of research outcomes, supporting the development of personalized medicine. The technology addresses challenges in traditional cell culture methods, potentially reducing costs and increasing efficiency in drug discovery processes.
What's Next?
Advanced Biomed plans to scale up the A+PerfusC™ system for high-throughput use and integrate AI-driven analytics for tumor profiling and cell therapy protocols. The company aims to expand its market presence and collaborate with research institutions to further refine the platform's capabilities. The success of this technology may lead to broader adoption in the biomedical industry, influencing research methodologies and treatment development strategies.
